This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Encompass Health (EHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Encompass Health (EHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Amedisys (AMED) Q2 Earnings Expected to Decline
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care
by Zacks Equity Research
Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.
Amedisys (AMED) Contessa's New JV Broadens At-Home Care Range
by Zacks Equity Research
Amedisys' (AMED) latest initiative aims at providing patients with a high-quality continuum of care in the home.
Are Options Traders Betting on a Big Move in Amedisys (AMED) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.
Amedisys (AMED) Down 11% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Investors are optimistic about the robust performances of Amedisys' (AMED) Home Health and Hospice segments.
Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays
by Zacks Equity Research
Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Impressive performance by the Home Health and Hospice segments drove Amedisys' (AMED) revenues in the first quarter.
Amedisys (AMED) Q1 Earnings Top Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 10.81% and 2.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Amedisys (AMED) Stock For Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.
Why Is Amedisys (AMED) Up 13.2% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for March 9th
by Zacks Equity Research
AGESY, AMED, and APAM have been added to the Zacks Rank #5 (Strong Sell) List on March 9, 2022.
New Strong Sell Stocks for March 4th
by Zacks Equity Research
AMED, CACC, and EXPO have been added to the Zacks Rank #5 (Strong Sell) List on March 4, 2022
Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.
Amedisys (AMED) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 0.86% and 0.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) Lags Q4 Earnings Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of -0.60% and 0.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for December 29th
by Zacks Equity Research
B, FPI, CGNX, AMED, and FSUGY have been added to the Zacks Rank #5 (Strong Sell) List on December 29, 2021.
New Strong Sell Stocks for December 27th
by Zacks Equity Research
TXRH, VIOT, WBK, AMED and CGNX have been added to the Zacks Rank #5 (Strong Sell) List on December 27, 2021
Why Is Amedisys (AMED) Down 22.9% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for December 2nd
by Zacks Equity Research
AMED, LGIH, SWK, TCMD, and HEINY have been added to the Zacks Rank #5 (Strong Sell) List on December 2, 2021.
New Strong Sell Stocks for November 26th
by Zacks Equity Research
COLD, ENR, KSU, FSTR, and AMED have been added to the Zacks Rank #5 (Strong Sell) List on November 26, 2021.
New Strong Sell Stocks for November 19th
by Zacks Equity Research
AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.
New Strong Sell Stocks for November 5th
by Zacks Equity Research
BLMN, AMED, HL, LGIH, and PLMR have been added to the Zacks Rank #5 (Strong Sell) List on November 5, 2021.
Amedisys (AMED) Tops Q3 Earnings Estimates, Slashes '21 View
by Zacks Equity Research
Amedisys (AMED) reports better-than-expected earnings for the third quarter on strong growth in the Home Health segment.